In the past week, APDN stock has gone down by -2.31%, with a monthly decline of -39.30% and a quarterly plunge of -59.12%. The volatility ratio for the week is 7.83%, and the volatility levels for the last 30 days are 12.13% for Applied Dna Sciences Inc The simple moving average for the past 20 days is -29.02% for APDN’s stock, with a -95.12% simple moving average for the past 200 days.
Is It Worth Investing in Applied Dna Sciences Inc (NASDAQ: APDN) Right Now?
APDN has 36-month beta value of 0.50. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APDN is 50.41M, and currently, short sellers hold a 1.21% ratio of that float. The average trading volume of APDN on November 12, 2024 was 11.55M shares.
APDN) stock’s latest price update
The stock of Applied Dna Sciences Inc (NASDAQ: APDN) has decreased by -2.25 when compared to last closing price of 0.19.Despite this, the company has seen a loss of -2.31% in its stock price over the last five trading days. accesswire.com reported 2024-10-30 that STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company. The offering is comprised of 20,312,500 shares (the “Shares”) of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.32 per share of common stock (or pre-funded warrants in lieu thereof, which shall have the same purchase price, less the exercise price of $0.0001) in a registered direct offering priced at-the-market under Nasdaq rules.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -71.60% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.20% of loss for the given period.
Volatility was left at 12.13%, however, over the last 30 days, the volatility rate increased by 7.83%, as shares sank -37.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -87.95% lower at present.
During the last 5 trading sessions, APDN fell by -1.77%, which changed the moving average for the period of 200-days by -98.51% in comparison to the 20-day moving average, which settled at $0.2566. In addition, Applied Dna Sciences Inc saw -98.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -4.39 for the present operating margin
- 0.16 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -2.17. The total capital return value is set at -1.09. Equity return is now at value -74.21, with -44.88 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -15.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 7.43.
Currently, EBITDA for the company is -10.45 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of -0.09. The receivables turnover for the company is 6.61for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.91.
Conclusion
To put it simply, Applied Dna Sciences Inc (APDN) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
